Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies.

Autor: Bhatt VR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA. vijaya.bhatt@unmc.edu.; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA. vijaya.bhatt@unmc.edu.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2024 Nov; Vol. 26 (11), pp. 1349-1354. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1007/s11912-024-01600-y
Abstrakt: Purpose of Review: To highlight the priorities in geriatric assessment research in myeloid malignancies and discuss design considerations necessary to ensure research is patient-centric, generalizeable, and high quality.
Recent Findings: Older adults with myeloid malignancies including those who are perceived to have excellent performance status have multiple functional impairments. These impairments are associated with early mortality. Older adults have different functional trajectories through the course of treatment; this will be further investigated in our ongoing multicenter study. In a single-center study, we have demonstrated the use of geriatric assessment to guide treatment is feasible. Key priorities include designing a multicenter validation study to confirm the role of geriatric assessment in determining treatment tolerance and survival. Such a study should include core geriatric assessment measures and should enroll diverse patient population across various practices. Conducting such a study is necessary to advance patient care and trial design, and to open venues to conduct studies to confirm the role of geriatric assessment in treatment selection.
Competing Interests: Declarations. Human and Animal Rights and Informed Consent: All reported studies/experiments with human or animal subjects performed by the author have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines). Conflict of Interest: VRB reports participating in Safety Monitoring Committee for Protagonist, serving as an Associate Editor for the journal, Current Problems in Cancer, and as a contributor for BMJ Best Practice, and receiving consulting fees from Imugene, research funding (institutional) from MEI Pharma, Actinium Pharmaceutical, Sanofi U.S. Services, Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Chimerix for a trial.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: